Exploiting mitochondrial targeting signal(s), TPP and bis‐TPP, for eradicating cancer stem cells (CSCs)

06-01-2018

TPP-related compounds may provide a novel chemical strategy for effectively targeting bulk cancer cells and CSCs, while minimizing off-target side-effects in normal cells.

Several independent lines of evidence support the idea that increased mitochondrial biogenesis or higher levels of mitochondrial protein translation may occur in CSCs.

For example, unbiased proteomics analysis directly shows that mitochondrial mass is elevated in CSCs.

High telomerase activity also directly correlated with high mitochondrial mass and the ability of CSCs to undergo proliferative expansion.

Similarly, high mitochondrial mass in CSCs was also specifically associated with mitochondrial ROS production and could be targeted with either: i) mitochondrial anti-oxidants, ii) inhibitors of mitochondrial biogenesis or OXPHOS, and even iii) inhibitors of cell proliferation.

Here, the researchers explored the hypothesis that TPP related compounds could be utilized to inhibit mitochondria in cancer stem cells.

Interestingly, these TPP related compounds were nontoxic and had little or no effect on ATP production in normal human fibroblasts, but selectively targeted adherent bulk cancer cells.

Therefore, these TPP related compounds successfully inhibited anchorage independent growth, which is normally associated with a metastatic phenotype.

In summary, the researchers showed that TPP related compounds provide a novel chemical strategy for effectively killing both i) bulk cancer cells and ii) CSCs, while specifically minimizing or avoiding off target side effects in normal cells.

Full text - http://www.aging-us.com/article/101384/text

Correspondence to - Michael P. Lisanti, Federica Sotgia; email: Michaelp.lisanti@gmail.com, fsotgia@gmail.com

About Aging-US:

Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.

Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed CentralWeb of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

Please visit our website at www.Aging-US.com and connect with us:

For media inquiries, please contact media@impactjournals.com.